Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

By S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, Nakorn Premsri, C. Namwat, M. de Souza, Elizabeth Adams and 14 more. New England Journal of Medicine, 2009

3,102 citations recorded by the source corpus.

Subfields: Infectious Diseases, Virology

View Paper: https://www.semanticscholar.org/paper/4ca89206d878735ba40d623300a6cf65890c1d18

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. Rafi Ahmed
2. Bali Pulendran

In Virology

1. Rafi Ahmed
2. Sonali Parbhoo

Citations in the corpus

• Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women (2010, neutral): “The successful trials tested medical male circumcision in South Africa (4), Kenya (5) and Uganda (6) (combined effectiveness in reducing HIV acquisition = 57%), sexually transmitted infection (STI) treatment in Tanzania (effectiveness in reducing HIV acquisition = 42%) (7) and a HIV vaccine combinat”
• Global trends in molecular epidemiology of HIV-1 during 2000–2007 (2011, background): “Recent encouraging results of a phase III HIV-1 vaccine efficacy trial in Thailand emphasize the importance of further studies on global and regional HIV diversity to inform rational vaccine design and development [23].”
• The immune response during acute HIV-1 infection: clues for vaccine development (2009, background): “The modest protection offered by the vaccines used in the recent RV144 clinical trial carried out in Thailand with volunteers at low risk of HIV-1 infectio”
• Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial (2012, neutral): “of infections) Placebo Low response Medium response High response 6267 (0) 2111 (0) 2312 (0) 2563 (0) 6199 (24) 2105 (6) 2304 (8) 2560 (3) 6127 (11) 2099 (6) 2302 (2) 2556 (4) 693 (13) 210 (4) 180 (6) 264 (2)”
• Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1 (2014, neutral): “therapies [3,4] and vaccines [5,6,7].”
• Immunological mechanisms of vaccination (2011, background): “The precise correlate of protection is under intense study, and the immune responses most consistently detected in this trial were CD4 + T cell proliferation, antibody-dependent cell-mediated cytotoxicity, and binding of antibodies to HIV-1 gp120 (ref”
• A Reinforcement Learning Design for HIV Clinical Trials (2014, methodology): “The vaccine was tested on 16 402 individuals making the trial the largest clinical trial for HIV vaccination to date (Rerks-Ngarm et al., 2009).”